Roche and Recursion Hunt New Brain Disease Targets
See how Roche is applying AI to reduce failure risk in brain-disease drug discovery.
30-Second TL;DR
What Changed
Roche is applying Recursion AI to discover new brain disease targets.
Why It Matters
Successful AI-enabled target discovery could shorten the time and cost required to identify viable drug candidates. It may also strengthen partnerships between pharmaceutical companies and specialized AI drug-discovery firms.
What To Do Next
Evaluate Recursion’s AI-enabled target-discovery platform for a pilot focused on ranking disease-relevant biological targets.
Key Points
- •Roche is applying Recursion AI to discover new brain disease targets.
- •The initiative focuses on improving early-stage drug discovery.
- •AI drug discovery companies aim to reduce failed clinical trials.
Weekly AI Recap
Read this week's curated digest of top AI events →
AI-curated news aggregator. All content rights belong to original publishers.
Original source: Bloomberg Technology ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.